| 摘要 |
PROBLEM TO BE SOLVED: To provide kits and methods for identifying a subject suitable for treatment with a therapeutic agent that modulates type I interferon activity among patients having type-I IFN or IFNα-mediated disorders.SOLUTION: Pharmaceutical compositions for treating systemic lupus erythematosus (lupus) with drugs are provided to a subject by identifying the subject suitable for treatment by detecting increased mRNA of at least four of pharmacodynamic (PD) markers containing therapeutic agents that modulates type I interferon activity, IFI27, IFI44, IFI44L, IFI6, and RSAD2, where an increase in mRNA of at least about 4 fold indicates the subject suitable for treatment. |
